Doximity shares soar 21% after company beats on revenue, raises fiscal year guidance

1. Doximity's stock surged 21% after beating Q3 fiscal 2025 revenue expectations. 2. Revenue reached $168.6 million, surpassing analyst estimates of $152.8 million. 3. Company raised fiscal year guidance to $564.6 million-$565.6 million, above previous estimates. 4. Unique provider engagement rose, with 610,000 using clinical workflow tools. 5. AI tool usage grew 60%, indicating strong future growth potential.